Donafenib and immunotherapy before surgery for advanced thyroid cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a combination of two drugs—donafenib (a targeted therapy) and an immunotherapy (anti-PD-1 antibody)—given before surgery for locally advanced differentiated thyroid cancer. The goal is to shrink the tumor to make surgery easier and more complete. If you have this type of thyroid cancer that is hard to remove completely with surgery alone, this study may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of thyroid cancer called differentiated thyroid cancer that is locally advanced (spread beyond the thyroid into nearby tissues like the throat, windpipe, or important blood vessels).
- You are between 18 and 80 years old.
- You have not had any prior cancer treatment for this condition.
- You are willing to have a biopsy of your tumor and to undergo the study procedures.
- Your overall health is good enough to handle the treatment (doctor's assessment score of 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug (a RET inhibitor) taken before surgery to help shrink thyroid cancer that has a specific genetic change (RET alteration). It may make surgery easier or more successful.
This study tests whether giving treatment before surgery (neoadjuvant therapy) helps people with locally advanced thyroid cancer. It aims to shrink the tumor so surgery can be more successful.
This trial tests a combination of two drugs, anlotinib (a targeted therapy) and benmelstobart (an immunotherapy), for people with differentiated thyroid cancer that has spread or cannot be removed. It may be an option if your cancer did not respond to or got worse after first treatment.
This trial tests a combination of two drugs (sinibolimab and lenvatinib) given before surgery. The goal is to shrink advanced thyroid cancer that cannot be fully removed otherwise, so that surgery can be more successful.
This trial tests whether the drug Surufatinib, given before surgery, can shrink locally advanced or metastatic thyroid cancer. It's a targeted therapy that blocks blood vessels that feed tumors, and is given as a pill to see if it makes the cancer easier to remove.
This trial tests adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy before surgery for advanced laryngeal or hypopharyngeal cancer. The goal is to see if this combination shrinks tumors more and improves outcomes for patients who need their entire voice box removed.
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.